NFIB is a Potential Target for Estrogen Receptor-negative Breast Cancers

Overview

Journal Mol Oncol

Specialties Molecular Biology
Oncology

Date 2011 Sep 20

PMID 21925980

Citations 31

Authors

Hyeong-Gon Moon

Ki-Tae Hwang

Jeong-Ah Kim

Hee Sung Kim

Min-Joo Lee

Eun-Mi Jung

Eunyoung Ko

Wonshik Han

Dong-Young Noh

Affiliations

Soon will be listed here.

Abstract

Background: The association between nuclear factor I/B (NFIB) gene and triple negative breast cancer has been previously suggested.

Methods: We investigated the relationship between NFIB mRNA and protein expression and molecular subtypes of breast cancer as well as the effect of NFIB silencing on the proliferation and apoptosis of breast cancer cells. Also, the clinical importance of NFIB expression was investigated in 163 breast cancer patients.

Results: By using 20 frozen human breast cancer tissues and various breast cancer cell lines, we observed a significant high level of NFIB mRNA level in triple negative breast cancer. NFIB protein was upregulated in ER negative breast cancer tissues but the expression level was similar between HER2 subtype and triple negative subtype. The clinical significance of NFIB was further examined in a tissue microarray from 163 invasive breast cancer patients, and the immunohistochemistry results showed a significant association between NFIB expression and nuclear grade, ER, and HER2 expression status. NFIB positive tumors were more likely to have high nuclear grade, ER negativity and HER2 over-expression. HCC1954 cells transfected with siRNA against NFIB showed a significant reduction in cell proliferation and increase in apoptotic signaling pathway.

Conclusions: Our results show a potential role of NFIB as a novel target in ER negative breast cancers.

Citing Articles

Biological mechanisms and clinical significance of endoplasmic reticulum oxidoreductase 1 alpha (ERO1α) in human cancer.

Chen P, Sharma A, Weiher H, Schmidt-Wolf I J Exp Clin Cancer Res. 2024; 43(1):71.

PMID: 38454454 PMC: 10921667. DOI: 10.1186/s13046-024-02990-4.

NFIB facilitates replication licensing by acting as a genome organizer.

Zhang W, Wang Y, Liu Y, Liu C, Wang Y, He L Nat Commun. 2023; 14(1):5076.

PMID: 37604829 PMC: 10442334. DOI: 10.1038/s41467-023-40846-1.

Triple-negative Breast Cancer: Identification of circRNAs With Efficacy in Preclinical Models.

Weidle U, Birzele F Cancer Genomics Proteomics. 2023; 20(2):117-131.

PMID: 36870692 PMC: 9989670. DOI: 10.21873/cgp.20368.

Systemically Identifying Triple-Negative Breast Cancer Subtype-Specific Prognosis Signatures, Based on Single-Cell RNA-Seq Data.

Xing K, Zhang B, Wang Z, Zhang Y, Chai T, Geng J Cells. 2023; 12(3).

PMID: 36766710 PMC: 9913740. DOI: 10.3390/cells12030367.

The NFIB/CARM1 partnership is a driver in preclinical models of small cell lung cancer.

Gao G, Hausmann S, Flores N, Benitez A, Shen J, Yang X Nat Commun. 2023; 14(1):363.

PMID: 36690626 PMC: 9870865. DOI: 10.1038/s41467-023-35864-y.

References

Mitani Y, Li J, Rao P, Zhao Y, Bell D, Lippman S . Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: Incidence, variability, and clinicopathologic significance. Clin Cancer Res. 2010; 16(19):4722-31. PMC: 5862426. DOI: 10.1158/1078-0432.CCR-10-0463. View

Italiano A, Ebran N, Attias R, Chevallier A, Monticelli I, Mainguene C . NFIB rearrangement in superficial, retroperitoneal, and colonic lipomas with aberrations involving chromosome band 9p22. Genes Chromosomes Cancer. 2008; 47(11):971-7. DOI: 10.1002/gcc.20602. View

Persson M, Andren Y, Mark J, Horlings H, Persson F, Stenman G . Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci U S A. 2009; 106(44):18740-4. PMC: 2773970. DOI: 10.1073/pnas.0909114106. View

Nagata K, Guggenheimer R, Enomoto T, Lichy J, Hurwitz J . Adenovirus DNA replication in vitro: identification of a host factor that stimulates synthesis of the preterminal protein-dCMP complex. Proc Natl Acad Sci U S A. 1982; 79(21):6438-42. PMC: 347141. DOI: 10.1073/pnas.79.21.6438. View

Geurts J, Schoenmakers E, Roijer E, Astrom A, Stenman G, Van de Ven W . Identification of NFIB as recurrent translocation partner gene of HMGIC in pleomorphic adenomas. Oncogene. 1998; 16(7):865-72. DOI: 10.1038/sj.onc.1201609. View

Moon H, Hwang K, Kim J, Kim H, Lee M, Jung E . NFIB is a potential target for estrogen receptor-negative breast cancers. Mol Oncol. 2011; 5(6):538-44. PMC: 5528324. DOI: 10.1016/j.molonc.2011.08.002. View

Fujita S, Ito T, Mizutani T, Minoguchi S, Yamamichi N, Sakurai K . miR-21 Gene expression triggered by AP-1 is sustained through a double-negative feedback mechanism. J Mol Biol. 2008; 378(3):492-504. DOI: 10.1016/j.jmb.2008.03.015. View

Karim-Kos H, de Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh J . Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer. 2008; 44(10):1345-89. DOI: 10.1016/j.ejca.2007.12.015. View

Moon H, Jeong S, Ju Y, Jeong C, Lee J, Lee Y . Up-regulation of RhoGDI2 in human breast cancer and its prognostic implications. Cancer Res Treat. 2010; 42(3):151-6. PMC: 2953778. DOI: 10.4143/crt.2010.42.3.151. View

10.

Qian F, Kruse U, Lichter P, Sippel A . Chromosomal localization of the four genes (NFIA, B, C, and X) for the human transcription factor nuclear factor I by FISH. Genomics. 1995; 28(1):66-73. DOI: 10.1006/geno.1995.1107. View

11.

Pierron A, Fernandez C, Saada E, Keslair F, Hery G, Zattara H . HMGA2-NFIB fusion in a pediatric intramuscular lipoma: a novel case of NFIB alteration in a large deep-seated adipocytic tumor. Cancer Genet Cytogenet. 2009; 195(1):66-70. DOI: 10.1016/j.cancergencyto.2009.06.009. View

12.

Hannafon B, Sebastiani P, de las Morenas A, Lu J, Rosenberg C . Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer. Breast Cancer Res. 2011; 13(2):R24. PMC: 3219184. DOI: 10.1186/bcr2839. View

13.

Kreike B, Van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H . Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res. 2007; 9(5):R65. PMC: 2242660. DOI: 10.1186/bcr1771. View

14.

Nahta R, Yu D, Hung M, Hortobagyi G, Esteva F . Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol. 2006; 3(5):269-80. DOI: 10.1038/ncponc0509. View

15.

Gronostajski R . Roles of the NFI/CTF gene family in transcription and development. Gene. 2000; 249(1-2):31-45. DOI: 10.1016/s0378-1119(00)00140-2. View

16.

Carey L, Dees E, Sawyer L, Gatti L, Moore D, Collichio F . The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007; 13(8):2329-34. DOI: 10.1158/1078-0432.CCR-06-1109. View

17.

. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365(9472):1687-717. DOI: 10.1016/S0140-6736(05)66544-0. View

18.

Selcuklu S, Donoghue M, Spillane C . miR-21 as a key regulator of oncogenic processes. Biochem Soc Trans. 2009; 37(Pt 4):918-25. DOI: 10.1042/BST0370918. View

19.

Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. DOI: 10.3322/caac.20107. View

20.

Nilsson M, Panagopoulos I, Mertens F, Mandahl N . Fusion of the HMGA2 and NFIB genes in lipoma. Virchows Arch. 2005; 447(5):855-8. DOI: 10.1007/s00428-005-0037-9. View